FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317892021> ?p ?o ?g. }

• W4317892021 endingPage "420" @default.
• W4317892021 startingPage "420" @default.
• W4317892021 abstract "420 Background: TLR-7/8 agonist has been suggested to be an effective immunotherapeutic agent, possible systemic side effect has forbid its clinical usage. A new controlled-releasing compound of TLR-7/8 agonist was developed to overcome the limitations, and this study aimed to evaluate efficacy and safety of this new compound in xenograft mouse model using cell-lines derived from triple conditional (Tcon) mouse which develop gastric cancer spontaneously. Methods: A cell line was established by tumor tissue in Tcon mouse which was developed by activation of Kras and suppression of E-cadherin and P53. Tcon cell line was evaluated its growth rate, sensitivity to anticancer agents and in vivo tumorigenicity. Tcon cell line was subcutaneously injected to the flank of the syngeneic mice, and 5-FU and/or TLR-7/8 agonist were administered into 4 groups of mice (control group, 5-FU alone, TLR-7/8 agonist alone, and combination of 5-FU and TLR-7/8). 5-FU was administered i.p(intra-peritoneal) in once a week and TLR-7/8 agonist was injected i.t(intra-tumoral) 3 times a week. Tumor size and mouse weight were measured for drug efficacy and safety. Immune profile of the tumor was analyzed by fluorescence-activated cell sorting. Results: Tcon cell-line show a rapid growth with 24 hours of doubling time, and good in vivo tumorigenicity in syngeneic mice. Cell-line showed moderate sensitivity to 5-FU and paclitaxel but resistance to oxaliplatin. Tumors in 5-FU alone group showed slight decrease in size compared with that in control group, However, TLR-7/8 agonist alone and combination significantly inhibited tumor growth. Weight loss or any significant side effect was not observed in any group. In immune profiling, TLR-7/8 mono or combination group showed increased levels of infiltrating CD4, CD8 T cells, and recruited NK cell as well as significantly increase M1/M2 ratio of macrophages compared to 5-FU alone or control group. Conclusions: A new controlled releasing system of TLR-7/8 agonist with or without 5-FU showed a excellent tumor inhibition efficacy with low toxicity in gastric cancer xenograft model. The effect seemed to be through multiple immune activations including cell-mediated immune response, M1 macrophage polarization as well as innate NK cells." @default.
• W4317892021 created "2023-01-25" @default.
• W4317892021 creator A5000736060 @default.
• W4317892021 creator A5011107729 @default.
• W4317892021 creator A5012765342 @default.
• W4317892021 creator A5021656135 @default.
• W4317892021 creator A5027745721 @default.
• W4317892021 creator A5045541621 @default.
• W4317892021 creator A5059766169 @default.
• W4317892021 creator A5061179490 @default.
• W4317892021 creator A5065461724 @default.
• W4317892021 creator A5067130362 @default.
• W4317892021 creator A5078263456 @default.
• W4317892021 creator A5079480597 @default.
• W4317892021 creator A5080361941 @default.
• W4317892021 creator A5082916969 @default.
• W4317892021 creator A5089617591 @default.
• W4317892021 creator A5090418595 @default.
• W4317892021 creator A5091184157 @default.
• W4317892021 date "2023-02-01" @default.
• W4317892021 modified "2023-10-16" @default.
• W4317892021 title "Inhibition of gastric cancer by a new controlled releasing compound of TLR-7/8 agonist via immune activation in a gastric cancer xenograft mice model." @default.
• W4317892021 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.420" @default.
• W4317892021 hasPublicationYear "2023" @default.
• W4317892021 type Work @default.
• W4317892021 citedByCount "0" @default.
• W4317892021 crossrefType "journal-article" @default.
• W4317892021 hasAuthorship W4317892021A5000736060 @default.
• W4317892021 hasAuthorship W4317892021A5011107729 @default.
• W4317892021 hasAuthorship W4317892021A5012765342 @default.
• W4317892021 hasAuthorship W4317892021A5021656135 @default.
• W4317892021 hasAuthorship W4317892021A5027745721 @default.
• W4317892021 hasAuthorship W4317892021A5045541621 @default.
• W4317892021 hasAuthorship W4317892021A5059766169 @default.
• W4317892021 hasAuthorship W4317892021A5061179490 @default.
• W4317892021 hasAuthorship W4317892021A5065461724 @default.
• W4317892021 hasAuthorship W4317892021A5067130362 @default.
• W4317892021 hasAuthorship W4317892021A5078263456 @default.
• W4317892021 hasAuthorship W4317892021A5079480597 @default.
• W4317892021 hasAuthorship W4317892021A5080361941 @default.
• W4317892021 hasAuthorship W4317892021A5082916969 @default.
• W4317892021 hasAuthorship W4317892021A5089617591 @default.
• W4317892021 hasAuthorship W4317892021A5090418595 @default.
• W4317892021 hasAuthorship W4317892021A5091184157 @default.
• W4317892021 hasConcept C121608353 @default.
• W4317892021 hasConcept C126322002 @default.
• W4317892021 hasConcept C150903083 @default.
• W4317892021 hasConcept C170493617 @default.
• W4317892021 hasConcept C203014093 @default.
• W4317892021 hasConcept C207001950 @default.
• W4317892021 hasConcept C2776090121 @default.
• W4317892021 hasConcept C2777292972 @default.
• W4317892021 hasConcept C2778938600 @default.
• W4317892021 hasConcept C502942594 @default.
• W4317892021 hasConcept C71924100 @default.
• W4317892021 hasConcept C86803240 @default.
• W4317892021 hasConcept C8891405 @default.
• W4317892021 hasConcept C98274493 @default.
• W4317892021 hasConceptScore W4317892021C121608353 @default.
• W4317892021 hasConceptScore W4317892021C126322002 @default.
• W4317892021 hasConceptScore W4317892021C150903083 @default.
• W4317892021 hasConceptScore W4317892021C170493617 @default.
• W4317892021 hasConceptScore W4317892021C203014093 @default.
• W4317892021 hasConceptScore W4317892021C207001950 @default.
• W4317892021 hasConceptScore W4317892021C2776090121 @default.
• W4317892021 hasConceptScore W4317892021C2777292972 @default.
• W4317892021 hasConceptScore W4317892021C2778938600 @default.
• W4317892021 hasConceptScore W4317892021C502942594 @default.
• W4317892021 hasConceptScore W4317892021C71924100 @default.
• W4317892021 hasConceptScore W4317892021C86803240 @default.
• W4317892021 hasConceptScore W4317892021C8891405 @default.
• W4317892021 hasConceptScore W4317892021C98274493 @default.
• W4317892021 hasIssue "4_suppl" @default.
• W4317892021 hasLocation W43178920211 @default.
• W4317892021 hasOpenAccess W4317892021 @default.
• W4317892021 hasPrimaryLocation W43178920211 @default.
• W4317892021 hasRelatedWork W1968220874 @default.
• W4317892021 hasRelatedWork W2020363833 @default.
• W4317892021 hasRelatedWork W2029401650 @default.
• W4317892021 hasRelatedWork W2045698890 @default.
• W4317892021 hasRelatedWork W2094219250 @default.
• W4317892021 hasRelatedWork W2187345403 @default.
• W4317892021 hasRelatedWork W2321614358 @default.
• W4317892021 hasRelatedWork W2342324886 @default.
• W4317892021 hasRelatedWork W2772062179 @default.
• W4317892021 hasRelatedWork W2943903912 @default.
• W4317892021 hasVolume "41" @default.
• W4317892021 isParatext "false" @default.
• W4317892021 isRetracted "false" @default.
• W4317892021 workType "article" @default.